Clinical study on tislelizumab combined with XELOX regimen in treatment of advanced gastric cancer
Objective To study clinical efficacy of Tislelizumab Injection combined with XELOX regimen in treatment of advanced gastric cancer.Methods Patients(60 cases)with advanced gastric cancer in Jingxian Hospital from January 2021 to January 2023 were divided into control(30 cases)and treatment groups(30 cases)according to the random number table method.Patients in the control group were treated with XELOX regimen:on the first day,they were iv administered with Oxaliplatin for injection,130 mg/m2,and also were po administered with Capecitabine Tablets,1 000 mg/m2,twice daily,continuous treatment for 14 d.Patients in the treatment group were iv administered with Tislelizumab Injection on the basis of the control group,200 mg/time,once every 3 weeks.A course had 3 weeks,and all patients were treated for 3 courses.Recent clinical efficacy,the immune function indicators and serum tumor markers in two groups were compared.Results The total effective rate of the treatment group was higher than that of the control group(P＜0.05).After treatment,CD3+ T cells,CD4+ T cells and CD4+ T/CD8+ T in control group were significantly decreased,while those in treatment group were significantly increased(P＜0.05).The immune function indicators in the treatment group were significantly higher than those in the control group(P＜0.05).After treatment,the serum levels of CA199,MMP-2,and VEGF in two groups were significantly decreased(P＜0.05),and the serum levels of tumor markers in the treatment group were lower than those in the control group(P＜0.05).Conclusion Tislelizumab Injection combined with XELOX regimen can improve the short-term efficacy in patients with advanced gastric cancer,promote the recovery of immune function and strengthen the anti-tumor effect.
Tislelizumab InjectionXELOX regimenOxaliplatin for injectionCapecitabine Tabletsadvanced gastric cancerCD3+ T cellCD4+ T cellCD4+ T/CD8+ TCA199MMP-2VEGF
NETL
NSTL
万方数据
